ANL
HEALTHCAREAdlai Nortye Ltd
$14.27-0.66 (-4.42%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving ANL Today?
No stock-specific AI insight has been generated for ANL yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.88$17.25
$14.27
Fundamentals
Market Cap$919M
P/E Ratio—
EPS$-1.11
Dividend Yield—
Dividend / Share—
ROE-4.1%
Profit Margin—
Debt / Equity—
Trading
Volume242K
Avg Volume (10D)—
Shares Outstanding58.7M
ANL News
15 articles- H.C. Wainwright Sees “Potential Best-in-Class Potency” for Adlai Nortye’s (ANL) Lead Asset, Lifts PTYahoo Finance·May 1, 2026
- Adlai Nortye (ANL): 10 Tiny Stocks That Are On Fire Right NowYahoo Finance·Apr 29, 2026
- Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year?Yahoo Finance·Apr 28, 2026
- Adlai Nortye Announces $150.0 Million Private Placement Equity FinancingGlobeNewswire Inc.·Apr 16, 2026
- Is Astellas Pharma (ALPMY) Stock Outpacing Its Medical Peers This Year?Yahoo Finance·Apr 10, 2026
- Adlai Nortye Ltd. Sponsored ADR (ANL) Upgraded to Buy: Here's WhyYahoo Finance·Mar 19, 2026
- Adlai Nortye Announces First Patient Enrolled in Global Phase 1 Trial of Pan-RAS (ON) Inhibitor AN9025 for Solid Tumors Harboring RAS MutationsYahoo Finance·Feb 12, 2026
- Adlai Nortye Announces $140.0 Million Private Placement Equity FinancingYahoo Finance·Feb 3, 2026
- Wall Street Set to Open Lower Friday as Investors React to Trump's Choice of Warsh as Fed ChairYahoo Finance·Jan 30, 2026
- Investors Calmed by Trump's Choice of Warsh as Fed Chair, Look Ahead to Inflation DataYahoo Finance·Jan 30, 2026
- Individual investors are Adlai Nortye Ltd.'s (NASDAQ:ANL) biggest owners and were rewarded after market cap rose by US$65m last weekYahoo Finance·Jan 28, 2026
- Adlai Nortye Enters Exclusive License Agreement with ASK Pharm for Pan-RAS (ON) Inhibitor AN9025 in Greater ChinaYahoo Finance·Dec 29, 2025
- Adlai Nortye to Participate in Upcoming Investor ConferencesYahoo Finance·Nov 21, 2025
- Adlai Nortye to Present Short Talk on AN4035 Preclinical Results at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsYahoo Finance·Oct 22, 2025
- Adlai Nortye to Present Short Talk at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsYahoo Finance·Oct 14, 2025
All 15 articles loaded
Price Data
Open$14.91
Previous Close$14.93
Day High$15.33
Day Low$14.68
52 Week High$17.25
52 Week Low$0.88
52-Week Range
$0.88$17.25
$14.27
Fundamentals
Market Cap$919M
P/E Ratio—
EPS$-1.11
Dividend Yield—
Dividend / Share—
ROE-4.1%
Profit Margin—
Debt / Equity—
Trading
Volume242K
Avg Volume (10D)—
Shares Outstanding58.7M
About Adlai Nortye Ltd
Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. The company is headquartered in Grand Cayman, the Cayman Islands.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—